NEWS

NEWS

Total 101

51
Preclinical Data on NT-I7 Published in Clinical Cancer Research
2022-01-24
50
NeoImmuneTech to Present at 2022 Biotech Showcase at J.P. Morgan Healthcare Conference
2022-01-05
49
NeoImmuneTech Presents Phase 1 Study Data at Society for Neuro-Oncology Annual Meeting
2021-11-22
48
NeoImmuneTech Presents Data in Three Posters at Society for Immunotherapy of Cancer Annual Meeting
2021-11-16
47
NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) in combination with PD-L1 checkpoint inhibitor in Frontline Locally Advanced or Metastatic Non-Small Cell Lung Cancer
2021-11-08
46
NeoImmuneTech Announces First Patient Dosed in Phase 1b Study of NT-I7 (efineptakin alfa) and Kymriah® (tisagenlecleucel) in Relapsed/Refractory Large B-Cell Lymphoma
2021-10-13
45
NeoImmuneTech to Present Three Posters at Society for Immunotherapy of Cancer Annual Meeting
2021-10-05
44
NeoImmuneTech to Present at Society for Neuro-Oncology Annual Meeting
2021-09-03
43
NeoImmuneTech Appoints Jean Fan, M.D., as Chief Clinical Officer
2021-08-25
42
NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 1 Study of NT-I7 (efineptakin alfa) for the Treatment of Kaposi Sarcoma in Patients With or Without HIV Infection
2021-07-26

<<<6 7 8 9 10 >>>